Krystal Biotech, Inc.
NASDAQKrystal Biotech heads into the final week of September with two sharply contrasting signals: Goldman Sachs just returned to the stock with a bullish stamp, while options traders have swung to their most defensive posture in months. The analyst picture is unambiguously constructive on its surface. Goldman reinstated coverage on September 24 with a Buy and a $441 target — the highest…
Snapshot as of 26 Sept 2026
Krystal Biotech heads into the final week of September with two sharply contrasting signals: Goldman Sachs just returned to the stock with a bullish stamp, while options traders have swung to their most defensive…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for KRYS — free to start on ORTEX.
Sign up for free →Open KRYS on ORTEX